Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 20, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company...
Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam
September 19, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical...
Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037
September 04, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company...
Foamix Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 07, 2019 16:05 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company...
Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea
August 05, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed
July 30, 2019 08:00 ET
|
Foamix, Ltd.
Foamix secures up to $50 million in non-dilutive funding Company secures $14 million via a registered direct offering of equity REHOVOT, Israel and BRIDGEWATER, N.J., July 30, 2019 (GLOBE...
Foamix Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8
July 24, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., July 24, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical-stage pharmaceutical company that specializes in...
Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology
June 04, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical-stage pharmaceutical company that specializes in...
Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 07, 2019 16:21 ET
|
Foamix, Ltd.
FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for Wednesday May 8th at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J., May 07, 2019 ...
Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
May 06, 2019 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), clinical stage specialty pharmaceutical company focused on developing...